Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
de Marinis F, Pereira JR, Fossella F, Perry MC, Reck M, Salzberg M, Jassem J, Peterson P, Liepa AM, Moore P, Gralla RJ. de Marinis F, et al. Among authors: peterson p. J Thorac Oncol. 2008 Jan;3(1):30-6. doi: 10.1097/JTO.0b013e31815e8b48. J Thorac Oncol. 2008. PMID: 18166838 Free article.
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Muñoz M, Reck M. Gridelli C, et al. Among authors: peterson p. J Thorac Oncol. 2007 Mar;2(3):221-9. doi: 10.1097/JTO.0b013e318031cd62. J Thorac Oncol. 2007. PMID: 17410045 Free article. Clinical Trial.
Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Pujol JL, Paul S, Chouaki N, Peterson P, Moore P, Berry DA, Salzberg M. Pujol JL, et al. Among authors: peterson p. J Thorac Oncol. 2007 May;2(5):397-401. doi: 10.1097/01.JTO.0000268672.57002.69. J Thorac Oncol. 2007. PMID: 17473654 Free article. Clinical Trial.
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.
Cullen MH, Zatloukal P, Sörenson S, Novello S, Fischer JR, Joy AA, Zereu M, Peterson P, Visseren-Grul CM, Iscoe N. Cullen MH, et al. Among authors: peterson p. Ann Oncol. 2008 May;19(5):939-45. doi: 10.1093/annonc/mdm592. Epub 2008 Feb 17. Ann Oncol. 2008. PMID: 18283036 Free article. Clinical Trial.
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
Scagliotti GV, Park K, Patil S, Rolski J, Goksel T, Martins R, Gans SJ, Visseren-Grul C, Peterson P. Scagliotti GV, et al. Among authors: peterson p. Eur J Cancer. 2009 Sep;45(13):2298-303. doi: 10.1016/j.ejca.2009.04.033. Epub 2009 May 25. Eur J Cancer. 2009. PMID: 19473833 Clinical Trial.
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Ciuleanu T, et al. Among authors: peterson p. Lancet. 2009 Oct 24;374(9699):1432-40. doi: 10.1016/S0140-6736(09)61497-5. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767093 Clinical Trial.
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Zhao YD, Liepa AM, Peterson P, Tonato M. Scagliotti GV, et al. Among authors: peterson p. J Thorac Oncol. 2009 Dec;4(12):1568-71. doi: 10.1097/JTO.0b013e3181c06980. J Thorac Oncol. 2009. PMID: 20009911 Free article. Clinical Trial.
1,675 results